Table 5.

HRs and 95% CIs for 1-yr stroke by drugs/procedures among the incident HD population with AF, 2006–2013

VariableModel 1Model 2Model 3
HR95% CIaHR95% CIaHR95% CI
Drugsa
 Warfarin0.700.65 to 0.760.720.66 to 0.770.820.71 to 0.94
 Calcium channel blockers0.910.83 to 1.000.890.81 to 0.990.870.77 to 0.99
β-blockers0.620.58 to 0.670.610.57 to 0.660.780.71 to 0.88
 Platelet aggregation inhibitors0.920.84 to 1.010.920.83 to 1.000.960.85 to 1.06
 Class III0.690.63 to 0.760.690.63 to 0.750.750.69 to 0.83
 Digoxin0.930.83 to 1.030.920.83 to 1.030.960.87 to 1.07
 NOACs0.900.51 to 1.590.890.50 to 1.560.890.50 to 1.56
Procedures
 Cardioversion0.990.77 to 1.301.050.81 to 1.371.100.84 to 1.43
 Catheter ablation1.170.76 to 1.801.240.80 to 1.911.280.83 to 1.98
 Surgical maze0.790.30 to 2.110.850.32 to 2.260.900.34 to 2.39
 Ambulatory event monitor0.550.38 to 0.790.550.38 to 0.810.600.41 to 0.86
 Defibrillator0.560.43 to 0.730.600.46 to 0.790.610.47 to 0.80
  • Model 1: Crude, unadjusted. Model 2: Adjusted for age, sex, race/ethnicity, dual eligibility, residential area, vintage, and median income. Model 3: Model 2+CHA2DS2-VASc+baseline and time-varying comorbidities (congestive heart failure, cancer, peripheral vascular disease, cerebrovascular disease, COPD, hypertension, current smoker status, atherosclerotic heart disease, diabetes, AIDS)+baseline and time-varying medications+baseline and time-varying procedures. aHR, adjusted hazard ratio. COPD, chronic obstructive pulmonary disease.

  • a Employed a competing-risks Cox model.